Hemispherx Biopharma and Chronix Biomedical Present Data on a Novel Diagnostic Approach for CFS at the IACFS/ME Biennial Conference
September 26, 2011 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 26, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) ("Hemispherx" or the "Company") announced that it presented new data on a blood test for Chronic Fatigue...
Hemispherx Biopharma's 2011 Stockholder Annual Meeting Set
September 19, 2011 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 19, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") will hold its Annual Meeting of stockholders on Thursday, October 13, 2011, at 10 a.m. EDT,...
Hemispherx Biopharma to Present at the Rodman and Renshaw 13th Annual Global Investment Conference
September 08, 2011 16:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 8, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), today announced that the Company will participate in the Rodman & Renshaw 13th Annual...
Hemispherx Biopharma Enters Into a Strategic Alliance With Armada Health Care for Alferon N Injection(R)
September 06, 2011 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 6, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex: HEB) (the "Company" or "Hemispherx"), announced that the Company has entered into a new agreement with Armada...
Breast Cancer Study With Hemispherx Biopharma's Ampligen(R) Commences
August 22, 2011 10:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 22, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE AMEX:HEB) announced that investigators from the Tumor Vaccine Group (TVG) at the University of Washington in Seattle, WA,...
Hemispherx Biopharma Submits for Regulatory Approval of Alferon(R) in Argentina
August 17, 2011 10:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 17, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced its authorized agent GP Pharm Argentina has submitted to the...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended June 30, 2011
August 05, 2011 16:41 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 5, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced its financial results for the three months ended June 30, 2011. The net loss (including non-cash...
FDA Authorizes New Hemispherx Biopharma Clinical Trial of Intranasal Ampligen(R) With Seasonal Influenza Vaccine
July 20, 2011 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 20, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced it has received U.S. Food Drug Administration (FDA)...
Hemispherx Biopharma Receives U.S. Patent Office Notification of New Patent Granted for the Use of Ampligen(R) as an Influenza Virus Vaccine Adjuvant for Protection Against Pandemic Avian Influenza
July 19, 2011 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 19, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced the granting of a new United States Patent for the use of...
Hemispherx Biopharma's Ampligen(R) Tested in Combination With Experimental Vaccine From Leading Cancer Research Institute
June 21, 2011 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, June 21, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced that it has entered into a Material Transfer and Research...